NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Talphera, Inc. (TLPH) Stock Analysis

Talphera, Inc. (TLPH) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TLPH

$1.07

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLPH with… →

TLPH Key Statistics

As of Oct 21, 2026
Trading
Open
$1.08
Previous Close
$1.07
Day's Range
1.05–1.13
52-Week Range
0.69–1.57
Volume
38.41K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$55.54M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.26
Financials (FY)
Revenue (FY)
$28.00K
Net Income (FY)
−$14.29M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.91M
1-Year Return
−5.31%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
189.49K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TLPH closed at $1.07, −5.31% over 1 year.

Talphera, Inc. (TLPH) has a market capitalization of $55.54M.

In fiscal 2025, TLPH reported revenue of $28.00K.

TLPH Stock Return by Calendar Year

Talphera, Inc. (TLPH) 10-year return: what $10,000 became

1 year
$10,000 $9,469
−5.31%
5 years
$10,000 $557
−94.43%
10 years
$10,000 $167
−98.33%

If you had invested $10,000 in Talphera, Inc. (TLPH) 10 years ago, at the close on October 21, 2016, it would have been worth $167 at the close on October 21, 2026: −98.33% in total, −33.58% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.14%
2025+119.23%
2024−29.73%
2023−67.26%
2022−79.82%
2021−54.84%
2020−41.23%
2019−8.66%
2018+13.79%
2017−21.92%
2016 (partial year)−27.58%

As of October 21, 2026.

TLPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$28.00K−$14.29M−51,035.7%
2024$0.00−$13.00M—
2023$651.00K−$18.40M−2,826.0%
2022$0.00$47.76M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$28.00K—−$13.48M−$14.29M−51,035.7%
2024$0.00—−$15.25M−$13.00M—
2023$651.00K—−$16.89M−$18.40M−2,826.0%
2022$0.00−$820.00K−$20.35M$47.76M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Talphera, Inc. (TLPH) is capitalised at $55.54M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 12 employees.

Over the past 52 weeks the price has ranged from $0.69 to $1.57. The most recent close on file for TLPH is $1.07, dated October 21, 2026. The close was unchanged from the previous session. The latest close sits 55.07% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $28.00K. The same year closed with a net loss of $14.29M. Earnings per share on a trailing basis come to −0.26.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $28.00K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.68. Annualized volatility over the trailing 10 years is 93.58%. The trailing one-year total return is −5.31%. Across 10 years the annualized return works out at −33.58%.

Growth & Income

No dividend is on file for TLPH.

Across the complete calendar years on file, 2025 returned +119.23% and 2022 returned −79.82%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −6.14% year to date.

Peer Comparison

Talphera, Inc. (TLPH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Talphera, Inc. TLPH $55.54M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Talphera, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Visit website →